In this week's Pharma Pulse, DHL breaks ground on a new cold chain hub at Singapore's Changi Airport, a new report finds pharma's commercial model in the middle of a fundamental reset, and the FDA grants accelerated approval to sevabertinib.
Commentary|Podcasts|January 24, 2024
Complying With the DSCSA
Author(s)Nicholas Saraceno, Senior Editor
Dave DeJean provides his expert insight on lessons he’s learned from his plethora of time in the industry, along with an outlook on where the pharma supply chain stands in adhering to the Drug Supply Chain Security Act (DSCSA).
Advertisement
In this exclusive PC Podcast interview, Dave DeJean, Systech’s VP of global strategic accounts, dives into:
- The valuable lessons he’s learned along the way, given his three and half decades of experience at Systech
- An overview of the Drug Supply Chain Security Act (DSCSA), including its three main pillars
- How he would interpret this “Stabilization Period” that the FDA provided this past summer, and what he pharma industry do now during this period in order to avoid penalties later
- Whether or not he anticipates the FDA implementing any other sort of delays in the near future in order to help remedy these issues/challenges surrounding the enactment of DSCSA
The latest episode of The Pharmaceutical Commerce Podcast is available directly on SoundCloud.
Advertisement
Related to this article
In this week's Pharma Pulse, the EU Council adopts the "pharma package," Commerce details 0% tariffs for certain drugs and Sharp expands autoinjector assembly capacity.
HDA's Kala Shankle says a federal licensure baseline could bring real efficiency gains for wholesale distributors and 3PLs, but only if state requirements align and every stakeholder moves on the same timeline.
With HRSA's approval window now closed, attention turns to whether health system pharmacies can reconcile rebates at scale before the pilot's Jan. 1 start.
In this week's Pharma Pulse, Vicapsys merges with Stateline, Veritiv targets GLP-1 shipping, Section 232 tariffs widen and HRSA's 340B rebate pilot deadline arrives.
Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.
CMS says 40 states and Puerto Rico have signed on to the GENEROUS Model, which applies MFN pricing to Medicaid drugs through state-invoiced rebates.
The EU's pharma reform makes market protection more conditional. Here is how US drugmakers, especially startups, can adapt and use IP to complement it.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Cardinal Health, McKesson Extend CVS Distribution Deals to 2032
2
What to Watch at LogiPharma: Resilience, Practical AI and New Peer Formats
3
Doceree CEO: AI Should Extend the Field Force, Not Replace It
4
Your Patient Support Data Shows What Happened. Can It Tell You Why?
5